Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urticaria10.01.06.001; 23.04.02.0010.004779%
Uveitis06.04.03.003; 10.02.01.0230.000858%
Vaginal discharge21.08.02.002--
Vaginal infection11.01.10.002; 21.14.02.002--
Ventricular fibrillation02.03.04.0080.000143%
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.10.012; 17.17.01.0110.002575%
Visual field defect06.02.07.003; 17.17.01.0010.002089%-
Visual impairment06.02.10.0130.003935%-
Vitreous haemorrhage06.10.03.001; 24.07.05.0050.000286%
Vomiting07.01.07.0030.004865%
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Vulvovaginal discomfort21.08.02.005---
Wheezing22.03.01.0090.000773%
Yellow skin08.01.03.046; 09.01.01.009; 23.03.03.0420.000215%-
Tubulointerstitial nephritis20.05.02.0020.000429%-
Acute generalised exanthematous pustulosis10.01.01.034; 11.07.01.018; 12.03.01.005; 23.03.10.0020.001216%-
Retinal toxicity06.09.03.013; 12.03.01.0360.002790%-
Peripheral swelling02.05.04.015; 08.01.03.053---
Red blood cell sedimentation rate increased13.01.03.001---
General physical health deterioration08.01.03.0180.000787%-
Muscle tightness15.05.03.007---
Neonatal hypoxia18.04.15.002; 22.11.02.0020.000143%-
Dyschezia07.02.03.0050.000143%-
Necrotising colitis07.08.01.0130.000215%-
Conjunctival hyperaemia06.04.01.0040.000143%-
Haemodynamic instability24.03.02.0060.000215%-
Lymphatic disorder01.09.01.003---
Musculoskeletal stiffness15.03.05.027---
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene